Tài liệu Báo cáo y học: " WT1 PEPTIDE VACCINATION IN COMBINATION WITH IMATINIB THERAPY FOR A PATIENT WITH CML

Although the Wilms’ tumor 1 (WT1) gene was first isolated as a tumor suppressor gene associated with the Wilms’ tumor, the WT1 gene has been shown to be highly expressed in hematopoietic malignancies including acute and chronic myelogenous leukemia, acute lymphocytic leukemia and myelodysplastic syndrome, and a majority of solid tumors including glioblastoma, lung cancer, breast cancer, colorectal cancer, thyroid cancer, renal cancer, bone/soft tissue sarcoma and head/neck squamous cell carcinoma [3]. WT1-specific CTLs with HLA-A*0201 or A*2402 could be generated by stimulating peripheral blood mono-nuclear cells (PB-MNCs) with WT1 peptide-pulsed presenting cells (APCs) in several laboratories [4-6]. WT1 peptides have already been used in clinical trials for specific immunotherapy of HLA-A24+ patients with brain tumor, breast cancer, colorectal cancer, thyroid cancer, leiomyosarcoma, or hematological malignancies including acute myeloid leukemia (AML), myeloma and myelodysplastic syndrome (MDS) [7].